How to buy Cyteir Therapeutics stock (Cyteir Therapeutics)

Cyteir Therapeutics is a biotechnology business based in the US. Cyteir Therapeutics shares (CYT) are listed on the NASDAQ and all prices are listed in US Dollars. Cyteir Therapeutics employs 46 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Cyteir Therapeutics stock

Buy Cyteir Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cyteir Therapeutics stock price (NASDAQ: CYT)

Use our graph to track the performance of CYT stocks over time.

Cyteir Therapeutics shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$2.99 - $3.19
50-day moving average more info button	$3.08
200-day moving average more info button	$2.93
Wall St. target price	$3.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.93

Is it a good time to buy Cyteir Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyteir Therapeutics financials

Gross profit TTM	$-16,591,000
Return on assets TTM	-14.5%
Return on equity TTM	-23.81%
Profit margin	0%
Book value	$3.47
Market Capitalization more info button	$108.7 million

TTM: trailing 12 months

Cyteir Therapeutics share dividends

We're not expecting Cyteir Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Have Cyteir Therapeutics's shares ever split?

Cyteir Therapeutics's shares were split on a 2:1 basis on 17 September 2014 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cyteir Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cyteir Therapeutics shares which in turn could have impacted Cyteir Therapeutics's share price.

Cyteir Therapeutics share price volatility

Over the last 12 months, Cyteir Therapeutics's shares have ranged in value from as little as $2.99 up to $3.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyteir Therapeutics's is 0.096. This would suggest that Cyteir Therapeutics's shares are less volatile than average (for this exchange).

To put Cyteir Therapeutics's beta into context you can compare it against those of similar companies.

• Sonnet Biotherapeutics (SONN.US): 1.045
• PDS Biotechnology (PDSB.US): 1.93
• Vertex Pharmaceuticals (VRTX.US): 0.394

Cyteir Therapeutics overview

Cyteir Therapeutics, Inc. , a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts. .

Frequently asked questions

null
What percentage of Cyteir Therapeutics is owned by insiders or institutions?
Currently 6.637% of Cyteir Therapeutics shares are held by insiders and 76.833% by institutions. How many people work for Cyteir Therapeutics?
Latest data suggests 46 work at Cyteir Therapeutics. When does the fiscal year end for Cyteir Therapeutics?
Cyteir Therapeutics's fiscal year ends in December. Where is Cyteir Therapeutics based?
Cyteir Therapeutics's address is: 128 Spring Street, Lexington, MA, United States, 02421 What is Cyteir Therapeutics's ISIN number?
Cyteir Therapeutics's international securities identification number is: US23284P1030